Translation Control Therapeutics
Bioinformatics algorithms that select tRNA codon pair for a protein of interest
Cerebio identifies a unique tRNA pair that is used with high frequency during the target protein’s translation but is not frequently used by the background human proteome. 85% of known proteins have a tRNA pair with such “signal to noise” ratio of at least 20. The full repertoire of human tRNAs (46 isoacceptors) has been purified and labeled with red and green fluorescent tags using Anima’s patented technology.
High content screening for mRNA translation modulators
When the selected “signature” pair is used in our screening system, a light pulse (FRET) is generated whenever the pair sits in a ribosome. With Translationlight, it is possible for the first time to visualize protein translation inside living cells. This capability allows Anima to discover compounds that control the process by either increasing or decreasing the translation of a specific mRNA in a selective manner. “Hit compounds” that decrease or increase the light emitted by the ribosomes are selected for further validation and analysis.
Proprietary selectivity analysis utilizing cloud-based big data single cell analysis of millions of images
Brightny validates the selectivity of Translationlight’s identified compounds by eliminating global translation modulators, analyzing the compound’s activity along the mRNA life cycle, checking the effect on similar proteins and critical pathways, and comparing the compounds to RNAi.
Mechanism of action and Target ID identification
Compass is Anima’s proprietary technology for the elucidation of compounds’ mechanisms of action and molecular targets in the novel target space of mRNA translation regulation. With assays and algorithms focused on the biology of mRNA maturation, transport, localization and translation, Compass rapidly answers the key questions of when, where and how the compounds work along the mRNA life cycle and highlights their eventual molecular targets.